Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) is an inhibitory immunoreceptor that negatively regulates T-cell activation. This paper presents preclinical characterization of the LAG-3 inhibitor, ieramilimab (LAG525), and phase I data for the treatment of patients with advanced/metastatic solid t...

Descripción completa

Detalles Bibliográficos
Autores principales: Schöffski, Patrick, Tan, Daniel S W, Martín, Miguel, Ochoa-de-Olza, María, Sarantopoulos, John, Carvajal, Richard D, Kyi, Chrisann, Esaki, Taito, Prawira, Amy, Akerley, Wallace, De Braud, Filippo, Hui, Rina, Zhang, Tian, Soo, Ross A, Maur, Michela, Weickhardt, Andrew, Krauss, Jürgen, Deschler-Baier, Barbara, Lau, Allen, Samant, Tanay S, Longmire, Tyler, Chowdhury, Niladri Roy, Sabatos-Peyton, Catherine A, Patel, Nidhi, Ramesh, Radha, Hu, Tiancen, Carion, Ana, Gusenleitner, Daniel, Yerramilli-Rao, Padmaja, Askoxylakis, Vasileios, Kwak, Eunice L, Hong, David S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883259/
https://www.ncbi.nlm.nih.gov/pubmed/35217575
http://dx.doi.org/10.1136/jitc-2021-003776

Ejemplares similares

Ejemplares similares